Biopharmaceutical companies launched only two initial public offerings in the US during August, but eight more drug developers entered the queue, setting up September to be another busy IPO month, rivaling July's nine offerings and June's 14.
Twenty-six of the 47 biopharma firms that went public in the first eight months of 2018 were trading in positive territory as of Aug. 31 and the average return was 16.9% (see table below), down from 20.9% as of July 3 for the 36 IPOs in the first half of this year. (Also see "IPO Update: Returns Ride Rollercoaster Into Mid-Year As More Biopharmas Take The Plunge" - Scrip, 4 July, 2018
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?